|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.000 USD | -2.44% |
|
-.--% | +46.28% |
| 06-02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 | |
| 05-26 | Diaceutics PLC Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 85.75 | 63.68 | 73.32 | 106.1 | 108.7 | 109.2 | - | - |
| Change | - | -25.74% | 15.14% | 44.67% | 2.47% | 0.49% | - | - |
| Enterprise Value (EV) 1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 101.5 | 97.09 | 90.33 |
| Change | - | -33.66% | 29.24% | 64.73% | 8.6% | 0.17% | -4.36% | -6.97% |
| P/E | - | 89.9x | -42x | -62.1x | - | - | - | - |
| PBR | - | 1.53x | 1.8x | 2.66x | 2.67x | 2.66x | 2.37x | 1.96x |
| PEG | - | - | 0x | 25.71x | - | - | - | - |
| Capitalization / Revenue | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 2.32x | 1.94x | 1.63x |
| EV / Revenue | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 2.16x | 1.72x | 1.35x |
| EV / EBITDA | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 9.81x | 7.05x | 4.97x |
| EV / EBIT | 120x | 76.4x | -18.8x | -38x | 57.5x | 31.7x | 18.9x | 9.63x |
| EV / FCF | -13.1x | 194x | -16x | -23.4x | -19.2x | 205x | 14.2x | 9.35x |
| FCF Yield | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.49% | 7.04% | 10.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1 |
| Rate of return | - | - | - | - | - | - | - | 77.5% |
| EPS 2 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 47 | 56.31 | 67.06 |
| EBITDA 1 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.35 | 13.77 | 18.16 |
| EBIT 1 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 5.149 | 9.381 |
| Net income 1 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 1.5 | 4.3 |
| Net Debt 1 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.71 | -12.14 | -18.9 |
| Reference price 2 | 1.020 | 0.755 | 0.870 | 1.255 | 1.280 | 1.290 | 1.290 | 1.290 |
| Nbr of stocks (in thousands) | 84,069 | 84,339 | 84,274 | 84,515 | 84,912 | 84,670 | - | - |
| Announcement Date | 22/03/22 | 17/04/23 | 21/05/24 | 13/05/25 | 26/05/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -87.88x | 18.74x | 46.59x | -.--% | 48.08B | |
| 30.29x | 2.25x | 19.42x | 1.57% | 3.3B | |
| 90.45x | 11.61x | 18.1x | 0.29% | 3.08B | |
| 28.43x | 3.8x | 15.4x | 0.63% | 1.28B | |
| -72.44x | - | - | 0.1% | 1.23B | |
| Average | -2.23x | 9.10x | 24.88x | 0.52% | 11.39B | |
| Weighted average by Cap. | -68.44x | 17.03x | 42.69x | 0.12% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- DIUXF Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
